Previous 10 | Next 10 |
2024-02-17 01:59:00 ET Wall Street analysts are quite bullish about Intellia Therapeutics (NASDAQ: NTLA) stock. On average, they're estimating that it'll rise by around 157% within the next 12 months. In the context of the new bull market shaping up right now, it likely has a good s...
Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the reach of gene editing to disease-causing targets in the lung CAMBRID...
2024-02-14 15:41:42 ET More on CRISPR, Intellia Therapeutics, etc. Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off Vertex, C...
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highli...
2024-02-08 21:37:41 ET Summary Intellia is adopting a distinct strategy by focusing on in-vivo gene editing, potentially redefining industry standards and expectations. Interim results from Intellia's in-vivo gene-editing program for ATTR amyloidosis show promising safety and effi...
Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single dose A single dose of NTLA-2002 led to 95% mean reduction in monthly HAE attack rate with 9 of 10 patients remaining completely attack free following ...
2024-01-27 08:55:00 ET Companies focusing on developing gene editing therapies have made significant progress over the past year. However, that has done little to keep Intellia Therapeutics (NASDAQ: NTLA) afloat. The biotech's stock has substantially lagged the broader market over t...
2024-01-25 10:57:50 ET Summary More than one year into the Launch of Zynteglo and Skysona, BLUE's sales remain underwhelming. The company launched a third gene therapy, Lyfgenia, but faces similar commercialization challenges. High treatment costs, limited patient base, outsou...
2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...
2024-01-21 08:00:00 ET You've probably heard that bleeding-edge biotechs like Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) are working hard to develop gene therapies to cure intractable hereditary illnesses. That's entirely true. But for invest...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
2024-04-14 05:55:00 ET The bull market is roaring higher, and many growth stocks have led the gains -- but this doesn't mean your opportunity to buy growth stocks for a good price is over. Plenty of players with great long-term prospects haven't yet benefited from this favorable market envi...
2024-04-12 04:50:00 ET Cathie Wood is known for her investments in disruptive technologies that are changing or have the potential to change the way things are done. She's built a solid reputation as a stock picker, aiming to beat the market over the long term by buying innovative companies...
2024-03-28 05:55:00 ET Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because she favors long-term investing. The idea is to buy promising companie...